These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16428338)

  • 1. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
    Morita H; Khanal S; Rastogi S; Suzuki G; Imai M; Todor A; Sharov VG; Goldstein S; O'Neill TP; Sabbah HN
    Am J Physiol Heart Circ Physiol; 2006 Jun; 290(6):H2522-7. PubMed ID: 16428338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.
    Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Tanhehco EJ; Goldstein S; Sabbah HN
    Cardiovasc Drugs Ther; 2002 May; 16(3):209-14. PubMed ID: 12374898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Goldstein S; Sabbah HN
    J Am Coll Cardiol; 2000 Jan; 35(1):222-9. PubMed ID: 10636284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure.
    Tanimura M; Sharov VG; Shimoyama H; Mishima T; Levine TB; Goldstein S; Sabbah HN
    Am J Physiol; 1999 Apr; 276(4):H1385-92. PubMed ID: 10199866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
    Rastogi S; Sharov VG; Mishra S; Gupta RC; Blackburn B; Belardinelli L; Stanley WC; Sabbah HN
    Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2149-55. PubMed ID: 18820026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.
    Rastogi S; Imai M; Sharov VG; Mishra S; Sabbah HN
    Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2475-82. PubMed ID: 18952719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dopamine beta-hydroxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
    Sabbah HN; Stanley WC; Sharov VG; Mishima T; Tanimura M; Benedict CR; Hegde S; Goldstein S
    Circulation; 2000 Oct; 102(16):1990-5. PubMed ID: 11034950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure.
    Zacà V; Rastogi S; Imai M; Wang M; Sharov VG; Jiang A; Goldstein S; Sabbah HN
    J Am Coll Cardiol; 2007 Aug; 50(6):551-7. PubMed ID: 17678740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
    Morita H; Suzuki G; Mishima T; Chaudhry PA; Anagnostopoulos PV; Tanhehco EJ; Sharov VG; Goldstein S; Sabbah HN
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):443-9. PubMed ID: 12652114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failure.
    Suzuki G; Khanal S; Rastogi S; Morita H; Mishima T; Anagnostopoulos PV; Nass O; Sharov VG; Tanhehco EJ; Goldstein S; Sabbah HN
    Cardiovasc Drugs Ther; 2007 Feb; 21(1):29-36. PubMed ID: 17294127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of Angiotensin-converting enzyme inhibitor.
    Sakata Y; Yamamoto K; Mano T; Nishikawa N; Yoshida J; Hori M; Miwa T; Masuyama T
    Circulation; 2004 May; 109(17):2143-9. PubMed ID: 15051632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.
    Peterson JT; Hallak H; Johnson L; Li H; O'Brien PM; Sliskovic DR; Bocan TM; Coker ML; Etoh T; Spinale FG
    Circulation; 2001 May; 103(18):2303-9. PubMed ID: 11342481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute ventricular reduction with the acorn cardiac support device: effect on progressive left ventricular dysfunction and dilation in dogs with chronic heart failure.
    Chaudhry PA; Anagnostopouls PV; Mishima T; Suzuki G; Nair H; Morita H; Sharov VG; Alferness C; Sabbah HN
    J Card Surg; 2001; 16(2):118-26. PubMed ID: 11766829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
    Suzuki G; Mishima T; Tanhehco EJ; Sharov VG; Todor A; Rostogi S; Gupta RC; Chaudhry PA; Anagnostopoulos PV; Nass O; Goldstein S; Sabbah HN
    Br J Pharmacol; 2003 Jan; 138(2):301-9. PubMed ID: 12540520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction.
    Sabbah HN; Shimoyama H; Kono T; Gupta RC; Sharov VG; Scicli G; Levine TB; Goldstein S
    Circulation; 1994 Jun; 89(6):2852-9. PubMed ID: 8205701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.
    Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Arnold M; Demers C; McKelvie RS; Liu PP
    J Card Fail; 2006 Sep; 12(7):514-9. PubMed ID: 16952784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.
    Hudson MP; Armstrong PW; Ruzyllo W; Brum J; Cusmano L; Krzeski P; Lyon R; Quinones M; Theroux P; Sydlowski D; Kim HE; Garcia MJ; Jaber WA; Weaver WD
    J Am Coll Cardiol; 2006 Jul; 48(1):15-20. PubMed ID: 16814643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure.
    Milliez P; Messaoudi S; Nehme J; Rodriguez C; Samuel JL; Delcayre C
    Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H435-41. PubMed ID: 19074674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure.
    Moe GW; Laurent G; Doumanovskaia L; Konig A; Hu X; Dorian P
    J Card Fail; 2008 Nov; 14(9):768-76. PubMed ID: 18995182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.